<DOC>
	<DOCNO>NCT00827177</DOCNO>
	<brief_summary>This open-label , dose-escalation study ARQ 197 administer orally combination sorafenib .</brief_summary>
	<brief_title>Dose Escalation Study ARQ 197 Combination With Sorafenib Adult Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>The study enrol patient expand cohort hepatocellular carcinoma , renal cell carcinoma , melanoma , non-small cell lung cancer , breast cancer . Enrollment initial patient cohort 3 6 patient follow traditional `` 3 + 3 '' dose escalation scheme . These patient treat ARQ 197 sorafenib Dose Level 1 ( ARQ 197 360 mg BID sorafenib 200 mg BID ) . Enrollment subsequent patient cohort ( ) depend safety tolerability combination treatment initial cohort . If &lt; 33 % patient treat Dose Level 1 experience dose-limiting toxicity ( y ) ( DLT ) end first treatment cycle ( 4 week ) , next cohort 6 patient enrol treated Dose Level 2 ( ARQ 197 360 mg BID sorafenib 400 mg BID ) . If ≥ 33 % patient treat Dose Level 1 experience DLT ( ) end first treatment cycle , next cohort 6 patient enrol treated Dose Level 0 ( ARQ 197 240 mg BID sorafenib 200 mg BID ) . Additional treatment cohort may enrol explore intermediate , high low dos ARQ 197 , indicate tolerability , safety profile , pharmacokinetic ( PK ) profile . Intra-patient dose-escalation Dose Level 1 Dose Level 2 may occur patient enrol Dose Level 1 complete least 1 cycle treatment without DLT drug-related adverse event , opinion Investigator Medical Monitor , serious medically significant . Once safe recommend dose level determine , expand cohort ( Expansion Cohort 1 ) 40 patient either unresectable HCC advance renal cell carcinoma ( RCC ) , sorafenib indicate , enrol treat dose level ( expansion portion ) . Up 20 patient unresectable HCC 20 patient advanced RCC may enrol protocol ( include patient dose-escalation cohort expansion cohort ) . An additional expansion cohort ( Expansion Cohort 2 ) 40 patient breast cancer , non-small cell lung cancer melanoma enrol treated MTD/RP2D . Up 10 patient may enrol breast non-small cell lung cancer 20 patient melanoma ( least 10 must NRAS mutation ) . Under Amendment # 3 , newly enrol subject HCC give ARQ 197 240 mg BID start dose . If patient HCC tolerate start dose least one cycle , investigator may increase his/her dose 360 mg BID .</detailed_description>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Written inform consent grant prior initiation studyspecific screen procedure 18 year age old Histologically cytologically confirm locally advance , inoperable metastatic solid tumor . In two expansion cohort , patient histologically cytologically confirm HCC , RCC , breast cancer , NSCLC melanoma eligible . An exception criterion patient HCC may enrol without histological confirmation disease long meet follow criterion diagnosis HCC ( protocol eligibility criterion ) : 1 . Lesion &gt; 2cm diameter 2. αfetoprotein ( AFP ) &gt; 200 ng/mL 3 . Radiological appearance mass suggestive HCC Measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) ≤1 Adequate bone marrow , liver , renal function , define : Platelet count ≥ 100 × 10^9/L ( ≥ 60 × 10^9/L HCC patient enrol expanded cohort ) Hemoglobin ≥ 10 g/dL Absolute neutrophil count ( ANC ) ≥1.5 × 10^9/L Total bilirubin ≤ 1.5 mg/dL ≤ 3 mg/dL HCC metastatic liver disease Alanine transaminase ( ALT ) aspartate transaminase ( AST ) ≤ 2.5 × upper limit normal ( ULN ) ≤ 5 × ULN HCC metastatic liver disease Serum creatinine ≤1.5 × ULN International normalize ratio ( INR ) 0.8 1.2 2 3 patient receive anticoagulant coumadin heparin . Patients therapeutically anticoagulated allowed participate provide prior evidence underlie abnormality exist parameter Women childbearing potential must negative pregnancy test perform within seven day prior start study drug Male female subject childbearing potential must agree use doublebarrier contraceptive measure , oral contraception , avoidance intercourse study 90 day last investigational drug dose receive Previous anticancer chemotherapy , radiotherapy , immunotherapy investigational agent within 4 week prior first day study define treatment follow exception : 1 ) prostate cancer patient androgen deprivation gonadotropinreleasing hormone ( GnRH ) agonists enrolled remains immunotherapy ; 2 ) patient receive palliative radiotherapy previous enrol therapy complete 1 week ( 7 day ) prior first day study define treatment patient recover radiotherapyrelated adverse event ( ) ; 3 ) patient currently sorafenib enrolled History cardiac disease : congestive heart failure define Class II IV per New York Heart Association ( NYHA ) classification ; active coronary artery disease ( CAD ) ; previously diagnose clinically significant bradycardia , uncontrolled cardiac arrhythmia define ≥ Grade 2 accord National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) ( version 3.0 ) , uncontrolled hypertension ; myocardial infarction occur within 6 month prior study entry ( myocardial infarction occur &gt; 6 month prior study entry permit ) Active clinically serious infection define ≥ Grade 2 accord NCI CTCAE , version 3.0 Substance abuse , medical , psychological social condition may , opinion Investigator , interfere patient 's participation study evaluation study result Any condition unstable could jeopardize safety patient his/her protocol compliance Known human immunodeficiency virus ( HIV ) infection Pregnancy breastfeed Inability swallow oral medication Significant gastrointestinal disorder , opinion Investigator , could interfere absorption ARQ 197 and/or sorafenib ( e.g . significant , uncontrolled inflammatory bowel disease extensive small bowel resection ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>dose escalation</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>tumor</keyword>
	<keyword>PK</keyword>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>renal cell carcinoma</keyword>
	<keyword>melanoma</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>breast cancer</keyword>
</DOC>